KR101187231B1 - 피부과 질병 치료용 이버멕틴의 외용 제형물 - Google Patents

피부과 질병 치료용 이버멕틴의 외용 제형물 Download PDF

Info

Publication number
KR101187231B1
KR101187231B1 KR1020057019402A KR20057019402A KR101187231B1 KR 101187231 B1 KR101187231 B1 KR 101187231B1 KR 1020057019402 A KR1020057019402 A KR 1020057019402A KR 20057019402 A KR20057019402 A KR 20057019402A KR 101187231 B1 KR101187231 B1 KR 101187231B1
Authority
KR
South Korea
Prior art keywords
mass
ivermectin
composition
oily phase
oils
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020057019402A
Other languages
English (en)
Korean (ko)
Other versions
KR20060004667A (ko
Inventor
빈센트 마네타
게리 알 왓킨스
Original Assignee
갈데르마 소시에떼아노님
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33312271&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101187231(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR0305048A external-priority patent/FR2854074B1/fr
Application filed by 갈데르마 소시에떼아노님 filed Critical 갈데르마 소시에떼아노님
Publication of KR20060004667A publication Critical patent/KR20060004667A/ko
Application granted granted Critical
Publication of KR101187231B1 publication Critical patent/KR101187231B1/ko
Assigned to 갈더마 홀딩 소시에떼 아노님 reassignment 갈더마 홀딩 소시에떼 아노님 권리의 전부이전등록 Assignors: 갈데르마 소시에떼아노님
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
KR1020057019402A 2003-04-24 2004-04-22 피부과 질병 치료용 이버멕틴의 외용 제형물 Expired - Lifetime KR101187231B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR0305048A FR2854074B1 (fr) 2003-04-24 2003-04-24 Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
FR03/05048 2003-04-24
US46899403P 2003-05-09 2003-05-09
US60/468,994 2003-05-09
PCT/EP2004/004950 WO2004093886A1 (en) 2003-04-24 2004-04-22 Topical formulation of ivermectin for the treatment of dermatological conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020127013727A Division KR101291824B1 (ko) 2003-04-24 2004-04-22 피부과 질병 치료용 이버멕틴의 외용 제형물

Publications (2)

Publication Number Publication Date
KR20060004667A KR20060004667A (ko) 2006-01-12
KR101187231B1 true KR101187231B1 (ko) 2012-10-02

Family

ID=33312271

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057019402A Expired - Lifetime KR101187231B1 (ko) 2003-04-24 2004-04-22 피부과 질병 치료용 이버멕틴의 외용 제형물

Country Status (16)

Country Link
US (6) US7550440B2 (cg-RX-API-DMAC10.html)
EP (1) EP1620113B1 (cg-RX-API-DMAC10.html)
JP (2) JP5711867B2 (cg-RX-API-DMAC10.html)
KR (1) KR101187231B1 (cg-RX-API-DMAC10.html)
AU (1) AU2004231323C1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0410503B8 (cg-RX-API-DMAC10.html)
CA (1) CA2522579C (cg-RX-API-DMAC10.html)
CY (2) CY1111797T1 (cg-RX-API-DMAC10.html)
FR (1) FR15C0069I2 (cg-RX-API-DMAC10.html)
HU (1) HUS1500048I1 (cg-RX-API-DMAC10.html)
LT (1) LTC1620113I2 (cg-RX-API-DMAC10.html)
LU (1) LU92915I2 (cg-RX-API-DMAC10.html)
MX (1) MXPA05011208A (cg-RX-API-DMAC10.html)
PL (2) PL378932A1 (cg-RX-API-DMAC10.html)
RU (1) RU2350333C3 (cg-RX-API-DMAC10.html)
WO (1) WO2004093886A1 (cg-RX-API-DMAC10.html)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2854074B1 (fr) 2003-04-24 2007-11-23 Galderma Res & Dev Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
WO2004093886A1 (en) * 2003-04-24 2004-11-04 Galderma S.A. Topical formulation of ivermectin for the treatment of dermatological conditions
MXPA05012791A (es) * 2003-05-25 2006-02-22 Wang Yuwan Formulacion sostenida que contiene dimeticona.
DE602005020912D1 (de) 2004-03-18 2010-06-10 Galderma Sa Ivermectin enthaltende creme
FR2867684B1 (fr) * 2004-03-18 2006-05-05 Galderma Sa Gel creme contenant de l'ivermectine
FR2883181B1 (fr) 2005-03-17 2007-05-18 Galderma Sa Composition a base d'une avermectine et d'acide azelaique notamment pour le traitement de la rosacee
FR2886850B1 (fr) * 2005-06-10 2007-10-05 Galderma Sa Composition a base d'une avermectine et de peroxyde de benzoyle notamment pour le traitement de la rosacee
FR2886852B1 (fr) * 2005-06-10 2007-11-23 Galderma Sa Composition a base d'une avermectine et d'hydrocortisone notamment pour le traitement de la rosacee
FR2886851B1 (fr) * 2005-06-10 2007-10-05 Galderma Sa Composition a base d'une avermectine et de metronidazole notamment pour le traitement de la rosacee
FR2894823B1 (fr) 2005-12-20 2008-02-29 Galderma Sa Composition de type emulsion inverse comprenant de l'ivermectine, et ses utilisations en cosmetique et en dermatologie
FR2900052B1 (fr) 2006-04-19 2011-02-18 Galderma Sa Composition comprenant au moins une phase aqueuse et au moins une phase grasse comprenant de l'ivermectine
FR2906468B1 (fr) * 2006-09-28 2012-09-21 Galderma Sa Utilisation de composes de la famille des avermectines pour le traitement de desordres dermatologiques
FR2907013B1 (fr) * 2006-10-12 2012-09-21 Galderma Sa Produits de soin cutane a double compartiment comprenant de l'ivermectine, et leurs utilisations
CA2666365C (en) * 2006-10-12 2016-08-09 Topaz Pharmaceuticals Llc Topical avermectin formulations and methods for elimination and prophylaxis of susceptible and treatment-resistant strains of head lice
FR2907012B1 (fr) * 2006-10-12 2012-09-21 Galderma Sa Composition dermatologique comprenant des nanocapsules d'avermectine, son procede de preparation et son utilisation
US8901163B2 (en) * 2007-01-03 2014-12-02 Galderma S.A. Method of treating hyperesthesia, paresthesia, dolor, and pruritus caused by insect stings or noxious weeds or plants using avermectin compound
DE102007056424A1 (de) * 2007-11-23 2009-05-28 Neopharmacie Gmbh Pharmazeutische Zusammensetzung, enthaltend eine Öl/Wasser-Emulsion
MX2011004442A (es) 2008-10-29 2011-10-14 Topaz Pharmaceuticals Inc Sistema conservante para formulaciones topicas terapeuticas basadas en emulsion.
US20120004200A1 (en) * 2008-12-23 2012-01-05 Galderma S.A. Topical pharmaceutical composition containing a water-sensitive active principle
ES2658897T3 (es) 2011-08-24 2018-03-12 Novan, Inc. Macromoléculas de liberación de óxido nítrico ajustables que tienen múltiples estructuras donantes de óxido nítrico
US8642665B2 (en) 2011-12-16 2014-02-04 Conopco, Inc. Environmentally friendly, low whitening compositions
JP5717034B2 (ja) * 2012-08-27 2015-05-13 丸和バイオケミカル株式会社 マクロライド系化合物を含有する土壌線虫防除用薬剤
FR3000397A1 (fr) * 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et d'ivermectine pour le traitement de la rosacee
CN103356687B (zh) 2012-10-19 2016-06-01 厦门大学 一种伊维菌素及其衍生物的用途
FR3003761B1 (fr) * 2013-03-29 2016-01-01 Galderma Sa Utilisation d'une lactone macrocyclique pour le traitement d'une infection par un papillomavirus
US9233117B2 (en) * 2013-07-08 2016-01-12 Galderma S. A. Treatment of inflammatory lesions of rosacea with ivermectin
US9782425B2 (en) 2013-07-08 2017-10-10 Galderma S.A. Treatment of papulopustular rosacea with ivermectin
EP3030266B1 (en) 2013-08-08 2020-10-28 Novan Inc. Topical compositions and methods of using the same
CN105916511A (zh) 2013-11-29 2016-08-31 盖尔德玛公司 用于治疗和/或预防特应性皮炎的阿维菌素家族或美贝霉素家族的化合物
CN104706584A (zh) * 2013-12-16 2015-06-17 天津迈迪瑞康生物医药科技有限公司 一种伊维菌素脂肪乳浓缩液、其制备方法及用途
US10322082B2 (en) 2014-07-11 2019-06-18 Novan, Inc. Topical antiviral compositions and methods of using the same
US20170232024A1 (en) 2014-08-04 2017-08-17 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
FR3026010B1 (fr) * 2014-09-18 2016-11-04 Galderma Sa Compositions comprenant un compose de la famille des avermectines et de la doxycycline pour le traitement de la rosacee
WO2016096795A1 (en) * 2014-12-15 2016-06-23 Galderma Sa Compound of the avermectin family for treating and/or preventing inflammatory dermatoses
WO2016096797A1 (en) 2014-12-15 2016-06-23 Galderma Sa Compound of the avermectin family in combination with an other active compound for treating and/or preventing inflammatory dermatoses
WO2017064205A1 (en) 2015-10-13 2017-04-20 Galderma Sa A process for preparing a stable emulsion comprising one or more avermectins
WO2017064206A1 (en) 2015-10-13 2017-04-20 Galderma Sa A process for preparing a composition comprising a high concentration of one or more avermectins
RU2738932C2 (ru) * 2016-08-04 2020-12-18 Нестле Скин Хелт Са Композиции и их применение для лечения или профилактики розацеа
US11160780B2 (en) * 2016-09-30 2021-11-02 Aurobindo Pharma Ltd. Pharmaceutical composition of ivermectin and process for preparation thereof
US11234959B2 (en) 2016-11-03 2022-02-01 Galderma Holding SA Compositions comprising a compound of the avermectin family for the treatment and/or prevention of hand eczema
EP3326614A1 (en) 2016-11-24 2018-05-30 Nestlé Skin Health SA Composition comprising avermectin compounds without solvents and propenetrating agents of avermectin compounds
EP3326608A1 (en) 2016-11-24 2018-05-30 Nestlé Skin Health SA Composition comprising avermectin compounds without solid fatty substances
EP3326609A1 (en) 2016-11-24 2018-05-30 Nestlé Skin Health SA Composition comprising avermectin compounds without gelling agents
KR20260035292A (ko) * 2017-06-12 2026-03-12 레이크우드 아메덱스, 인크. 비스포스포신 겔 제제 및 이의 용도
CN119157876A (zh) 2017-12-15 2024-12-20 塔苏斯制药有限公司 用于治疗睑炎的异恶唑啉驱虫剂制剂和方法
CN112638490B (zh) 2018-06-15 2023-01-03 格雷斯公司 消泡剂活性物质、其制造方法和消泡制剂
WO2020064843A1 (en) * 2018-09-28 2020-04-02 Galderma Research & Development Pharmaceutical composition in the form of a water-in-oil emulsion (w/o) and its uses
US12502377B2 (en) 2019-04-04 2025-12-23 Tarsus Pharmaceuticals, Inc. Method of eradicating ticks that attach to humans using lotilaner formulations
CA3136356A1 (en) 2019-04-12 2020-10-15 Ecolab Usa Inc. Antimicrobial multi-purpose cleaner and methods of making and using the same
US12161752B2 (en) 2019-08-20 2024-12-10 Vishwanath Padmanabhan Compositions and methods for the treatment of anterior blepharitis and posterior blepharitis
AU2020333860A1 (en) * 2019-08-21 2022-04-07 Leo Pharma A/S Solvent delivery system for topical delivery of active agents
KR102480430B1 (ko) 2020-10-21 2022-12-21 순천향대학교 산학협력단 주사증 진단을 위한 마이크로RNA-31-5p 및 이의 용도
KR20220052474A (ko) 2020-10-21 2022-04-28 순천향대학교 산학협력단 주사증 진단을 위한 마이크로RNA-21-3p 및 이의 용도
US11291679B1 (en) * 2021-03-22 2022-04-05 Mountain Valley Md Inc. Injectable, infusable, instillable ivermectin adjuvant for cancer therapies
EP4062907A1 (fr) 2021-03-23 2022-09-28 Substipharm Formulation par voie orale d'ivermectine et utilisations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020061855A1 (en) * 2000-06-29 2002-05-23 Parks L. Dean Method of treating acne vulgaris using avermectin compound

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5332577A (en) * 1988-12-27 1994-07-26 Dermamed Transdermal administration to humans and animals
GB9422306D0 (en) * 1994-11-04 1994-12-21 Sandoz Ltd Organic compounds
US5952371A (en) * 1996-10-16 1999-09-14 Merck & Co., Inc. Triterpene derivatives with immunosuppressant activity
RU2138268C1 (ru) * 1997-09-22 1999-09-27 Мосин Владимир Александрович Средство, подавляющее пролиферацию и вызывающее гибель опухолевых клеток, при этом защищающее нормальные клетки
US5952372A (en) * 1998-09-17 1999-09-14 Mcdaniel; William Robert Method for treating rosacea using oral or topical ivermectin
US6310968B1 (en) * 1998-11-24 2001-10-30 Picker International, Inc. Source-assisted attenuation correction for emission computed tomography
MXPA01007486A (es) * 1999-01-25 2003-06-24 Optime Therapeutics Inc Formulaciones de liposomas.
US6133310A (en) * 1999-08-26 2000-10-17 Parks; L. Dean Method of treatment of rosacea
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6319945B1 (en) * 2000-06-29 2001-11-20 L. Dean Parks Method of treatment of seborrheic dermatitis
US20030064940A1 (en) * 2001-10-02 2003-04-03 Parks L. Dean Kit for treating acne vulgaris using avermectin compound
US6399651B1 (en) * 2000-06-29 2002-06-04 L. Dean Parks Method of treating dermatoses using avermectin compound
DE10063946A1 (de) * 2000-12-20 2002-07-04 Basf Ag Verwendung von Lichtschutzmittelkombinationen, die als wesentlichen Bestandteil 2,2'-p-Phenylen-bis(3,1-benzoxazin-4-on) enthalten als photostabile UV-Filter in kosmetischen und pharmazeutischen Zubereitungen
EP1476121A4 (en) * 2002-02-08 2010-10-27 Merck Sharp & Dohme TOPICAL IVERMECTIN COMPOSITION
WO2003075656A2 (en) * 2002-03-04 2003-09-18 Divergence, Inc. Nematicidal fatty acid and fatty acid ester related compounds
WO2004093886A1 (en) * 2003-04-24 2004-11-04 Galderma S.A. Topical formulation of ivermectin for the treatment of dermatological conditions
DE602005020912D1 (de) * 2004-03-18 2010-06-10 Galderma Sa Ivermectin enthaltende creme
FR2867684B1 (fr) 2004-03-18 2006-05-05 Galderma Sa Gel creme contenant de l'ivermectine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020061855A1 (en) * 2000-06-29 2002-05-23 Parks L. Dean Method of treating acne vulgaris using avermectin compound

Also Published As

Publication number Publication date
US20060100165A1 (en) 2006-05-11
US7550440B2 (en) 2009-06-23
US20120077766A1 (en) 2012-03-29
LTC1620113I2 (lt) 2018-02-26
PL378932A1 (pl) 2006-06-12
AU2004231323B2 (en) 2009-12-10
BRPI0410503B8 (pt) 2021-05-25
FR15C0069I2 (fr) 2016-04-22
RU2005136438A (ru) 2006-05-27
EP1620113A1 (en) 2006-02-01
US8093219B2 (en) 2012-01-10
US8415311B2 (en) 2013-04-09
MXPA05011208A (es) 2005-12-14
CY2016031I2 (el) 2017-03-15
CA2522579C (en) 2012-08-28
AU2004231323C1 (en) 2016-11-03
CA2522579A1 (en) 2004-11-04
US20120258062A1 (en) 2012-10-11
BRPI0410503A (pt) 2006-06-20
HUS1500048I1 (hu) 2017-10-30
FR15C0069I1 (cg-RX-API-DMAC10.html) 2015-12-04
US8080530B2 (en) 2011-12-20
WO2004093886A1 (en) 2004-11-04
US20090252797A1 (en) 2009-10-08
EP1620113B1 (en) 2011-07-13
LU92915I2 (fr) 2016-02-17
US8470788B2 (en) 2013-06-25
JP5538461B2 (ja) 2014-07-02
PL1620113T3 (pl) 2011-10-31
AU2004231323A1 (en) 2004-11-04
US8598129B2 (en) 2013-12-03
US20130209381A1 (en) 2013-08-15
RU2350333C2 (ru) 2009-03-27
BRPI0410503B1 (pt) 2018-07-10
RU2350333C3 (ru) 2018-08-24
US20090227668A1 (en) 2009-09-10
CY2016031I1 (el) 2017-03-15
JP2006524212A (ja) 2006-10-26
CY1111797T1 (el) 2015-10-07
JP2012126738A (ja) 2012-07-05
JP5711867B2 (ja) 2015-05-07
KR20060004667A (ko) 2006-01-12

Similar Documents

Publication Publication Date Title
KR101291824B1 (ko) 피부과 질병 치료용 이버멕틴의 외용 제형물
CA2522579C (en) Topical formulation of ivermectin for the treatment of dermatological conditions
EP2010148B1 (fr) Composition comprenant au moins une phase aqueuse et au moins une phase grasse comprenant de l'ivermectine
US8858967B2 (en) Dermatological cream-gels containing avermectin compounds
US20160303152A1 (en) Topical Composition of Ivermectin
US10744112B2 (en) Composition comprising avermectin compounds without solvents and propenetrating agents of avermectin compounds
US20160303151A1 (en) Topical Composition of Ivermectin
HK1198004A (en) Topical formulation of ivermectin for the treatment of dermatological conditions

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20051012

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20090421

Comment text: Request for Examination of Application

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110407

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20120323

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20110407

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
AMND Amendment
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20120525

PJ0201 Trial against decision of rejection

Patent event date: 20120525

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20120323

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20120705

Appeal identifier: 2012101005047

Request date: 20120525

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20120525

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20120525

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20110907

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20090507

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20090421

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20120705

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20120626

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20120925

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20120925

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20150827

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20150827

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20160831

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20160831

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20180903

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20180903

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20190829

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20190829

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20200917

Start annual number: 9

End annual number: 9

PC1801 Expiration of term

Termination date: 20241022

Termination category: Expiration of duration